CTI BioPharma Gross Profit

CTI BioPharma posts a gross profit of $71M as of March 2023. That compares with $2M in the prior-year period — up 3435.4% year over year. That is below the Healthcare sector average of $65B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, CTI BioPharma's gross profit was $2M. The latest reading is $71M — a 3435.4% year-over-year increase (period ending March 2023). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a gross profit near $65B is typical. CTI BioPharma's $71M is lower that level. That is roughly 99.9% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Gross Profit is one piece of CTI BioPharma's financial statement story. At $71M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CTIC's gross profit usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $65B), and (3) consistency with growth and profitability. This page covers the first two; CTI BioPharma's other metric pages and overview cover the third.